NewAmsterdam Pharma (NAMS) Other financing activities (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Other financing activities of $10.4 million for Q1 2026, up 5590.71% on a YoY basis from $183000.0 in Q1 2025, and down 64.1% sequentially from $29.0 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Other financing activities (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Other financing activities data on file, last reported at $10.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 5590.71% year-over-year to $10.4 million; the trailing twelve-month figure through Mar 2026 stood at $39.7 million (up 193.98% YoY), and the FY2025 full-year result was $29.5 million, up 114.14% from the prior year.
- Other financing activities fell to $10.4 million in Q1 2026, from $29.0 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $29.0 million in Q4 2025 to a low of -$10.9 million in Q3 2025.
- A 4-year average of $5.2 million and a median of $4.3 million in 2023 frame the typical range for Other financing activities.
- Peak annual rise in Other financing activities reached 8432.35% in 2025, while the deepest fall reached 183.88% in 2025.
- Tracing NAMS's Other financing activities over 4 years: stood at $8.3 million in 2023, then plunged by 95.92% to $340000.0 in 2024, then jumped by 8432.35% to $29.0 million in 2025, then plunged by 64.1% to $10.4 million in 2026.
- Business Quant data shows NAMS's Other financing activities at $10.4 million in Q1 2026, $29.0 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.41 Mn |
| Mar 31, 2026 | 10.41 Mn |
| Dec 31, 2025 | 29.01 Mn |
| Dec 31, 2025 | 29.01 Mn |
| Sep 30, 2025 | -10.89 Mn |
| Sep 30, 2025 | -10.89 Mn |
| Jun 30, 2025 | 11.16 Mn |
| Jun 30, 2025 | 11.16 Mn |
| Mar 31, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Dec 31, 2024 | 340,000.00 |
| Dec 31, 2024 | 340,000.00 |
| Sep 30, 2024 | 12.98 Mn |
| Sep 30, 2024 | 12.98 Mn |
| Mar 31, 2024 | 440,000.00 |
| Mar 31, 2024 | 440,000.00 |
| Dec 31, 2023 | 8.33 Mn |
| Dec 31, 2023 | 8.33 Mn |
| Sep 30, 2023 | -8.33 Mn |
| Sep 30, 2023 | -8.33 Mn |